COVID-19 & Cancer

COVID-19 & Cancer

Early in 2020, we watched with growing alarm as early warnings of the virulence of SARS-CoV-2 started pouring in from Wuhan, and later, from Lombardy. At The Cancer Letter, we quickly decided to chart a course for intensive coverage of the pandemic as it reached our shores—oncologists are well-poised to take the lead in shaping research on COVID-19, and exposure mitigation strategies for high-risk patients. This coverage is collected here.
NCTN group chairs: Cancer trials take backseat to clinical care amid COVID-19 pandemic
COVID-19 & CancerFreeGuest Editorial

NCTN group chairs: Cancer trials take backseat to clinical care amid COVID-19 pandemic

While the National Clinical Trials Network (NCTN) groups remain open for business during the pandemic, it’s not business as usual. For good reason, clinical trials are taking a backseat to clinical care. Leadership and members themselves face significant challenges treating oncology patients, as attention and resources are diverted to minister to those with COVID-19.
By Charles D. Blanke, Douglas S. Hawkins, Monica M. Bertagnolli, Peter J. O'Dwyer, Mitchell D. Schnall, Walter J. Curran, Norman Wolmark, Robert S. Mannel and Janet Dancey